Raj JD - Seelos Therapeutics Chairman, Founder

All Insiders . USA . 
Stock . Seelos Therapeutics . Stakeholders . Insider . Raj JD
SEEL Stock  USD 0.39  0.11  22.00%   

Insider

Raj JD is Chairman, Founder of Seelos Therapeutics
Age 64
Phone646 293 2100
Webhttps://seelostherapeutics.com

Seelos Therapeutics Management Efficiency

The company has return on total asset (ROA) of (2.6111) % which means that it has lost $2.6111 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.842) %, meaning that it created substantial loss on money invested by shareholders. Seelos Therapeutics' management efficiency ratios could be used to measure how well Seelos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Seelos Therapeutics currently holds 14.23 M in liabilities with Debt to Equity (D/E) ratio of 0.73, which is about average as compared to similar companies. Seelos Therapeutics has a current ratio of 3.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Seelos Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Seelos Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Seelos Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Seelos to invest in growth at high rates of return. When we think about Seelos Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Brian MDRezolute
49
Seth LewisMolecular Partners AG
N/A
RAC SakaiTempest Therapeutics
N/A
Robyn SweinhartRezolute
N/A
Andreas EMBAMolecular Partners AG
58
Joseph HazeltonDyadic International
48
Petpiboon PrasitTempest Therapeutics
N/A
Edward CalamaiDiaMedica Therapeutics
N/A
Christopher RoenfeldtForte Biosciences
N/A
Alexander ZurcherMolecular Partners AG
49
LLM JDRezolute
63
Dr DubenskyTempest Therapeutics
66
Patrick AmstutzMolecular Partners AG
49
Antony CPAForte Biosciences
57
Scott CADiaMedica Therapeutics
59
Justin TrojanowskiTempest Therapeutics
36
, MBAMolecular Partners AG
51
Thomas SchwerzmannMolecular Partners AG
N/A
Michael PitznerMolecular Partners AG
N/A
Dominic CundariDiaMedica Therapeutics
73
Daniel RyweckSilo Pharma
59
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York. Seelos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people. Seelos Therapeutics [SEEL] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Return On Equity-5.84
Return On Asset-2.61

Seelos Therapeutics Leadership Team

Elected by the shareholders, the Seelos Therapeutics' board of directors comprises two types of representatives: Seelos Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Seelos. The board's role is to monitor Seelos Therapeutics' management team and ensure that shareholders' interests are well served. Seelos Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Seelos Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Gopal Krishna, Head Operations
Michael Golembiewski, Chief Officer
Kimberly Farrand, Senior Operations
Raj JD, Chairman, Founder
Anthony Marciano, Chief Officer
Karen Fusaro, Senior Operations
Tim MD, Chief Officer

Seelos Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Seelos Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-5.84
Return On Asset-2.61
Profit Margin2.03 %
Operating Margin(8.35) %
Current Valuation10.45 M
Shares Outstanding581 K
Shares Owned By Insiders0.49 %
Shares Owned By Institutions4.46 %
Number Of Shares Shorted170.89 K
Price To Book15.10 X

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Other Information on Investing in Seelos OTC Stock

Seelos Therapeutics financial ratios help investors to determine whether Seelos OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Seelos with respect to the benefits of owning Seelos Therapeutics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY